Verrica Pharmaceuticals

General Information


We are a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. Our lead product candidate, VP-102, is a proprietary drug-device combination of our novel topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through our single-use precision applicator. We are initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Employees: 11
Founded: 2013
Contact Information
Address 10 North High Street, Suite 200, West Chester, PA 19380, US
Phone Number (484) 453-3300
Web Address
View Prospectus: Verrica Pharmaceuticals
Financial Information
Market Cap $374.2mil
Revenues $0 mil (last 12 months)
Net Income $-11.1 mil (last 12 months)
IPO Profile
Symbol VRCA
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Jefferies/ Cowen
CO-Managers -
Expected To Trade: 6/15/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change